drugset
drugset / Trial / NCT00769886

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

NCT00769886 ↗

Phase 3 Completed 144 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.

Timeline

Start
2008-10
Primary completion
2008-12
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketotifen Small molecule 0.025 % Other
Subject Naphazoline Small molecule 0.05 % Other

Indications

conjunctivitis